The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect
Abstract
Objective: To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). Methods: In a 12‐week randomized, double‐blind trial, ALS and MS patients with clinically significant PBA (a baseline score ≥13 on the Center for Neurologic Studies–Lability Scale [CNS‐LS]) were maintained, twice daily, on placebo, DMq at 30/10mg (DMq‐30), or DMq at 20/10mg (DMq‐20). Results: In 326 randomized patients (of whom 283, or 86.8%, completed the study), the PBA‐episode daily rate was 46.9% (p< 0.0001) lower for DMq‐30 than for placebo and 49.0% (p< 0.0001) lower for DMq‐20 than for placebo by longitudinal negative binomial regression, the prespecified primary analysis. Mean CNS‐LS scores decreased by 8.2 points for DMq‐30 and 8.2 for DMq‐20, vs 5.7 for placebo (p= 0.0002 and p= 0.0113, respectively). Other endpoints showing statistically significant DMq benefit included, for both dosage levels, the likelihood of PBA remission during the final 14 days and, for the higher dosage, improvement on measures of social functioning and mental health. Both dosages were safe and well tolerated. Interpretation: DMq markedly reduced PBA frequency and severity, decreasing the condition's detrimental impact on a patient's life, with satisfactory safety and high tolerability. The findings expand the clinical evidence that DMq may be an important treatment for patients suffering from the socially debilitating symptoms of PBA. Ann Neurol 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Self-citationEconometric Models for Count Data with an Application to the Patents-R & D Relationship
Hausman, J., Hall, B. H., & Griliches, Z. (1984) · Econometrica · doi:10.2307/1911191 · Cited by 3,393
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Self-citationMiller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston, W., Kalra, S., Katz, J. S., Mitsumoto, H., Rosenfeld, J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc01a4 · Cited by 674
Frison, L., & Pocock, S. J. (1992) · Statistics in Medicine · doi:10.1002/sim.4780111304 · Cited by 593
Miller, R. G., Rosenberg, J. A., Gelinas, D. F., Mitsumoto, H., Newman, D., Sufit, R., Borasio, G. D., Bradley, W. G., Bromberg, M. B., Brooks, B. R., et al. (1999) · Neurology · doi:10.1212/wnl.52.7.1311 · Cited by 574
Self-citationSenn, S., Frison, L., & Pocock, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780130210 · Cited by 529
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial
Brooks, B. R., Thisted, R. A., Appel, S. H., Bradley, W. G., Olney, R. K., Berg, J. E., Pope, L. E., & Smith, R. A. (2004) · Neurology · doi:10.1212/01.wnl.0000142042.50528.2f · Cited by 434
Self-citation(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.2.286 · Cited by 337
House, A., Dennis, M., Molyneux, A., Warlow, C., & Hawton, K. (1989) · BMJ · doi:10.1136/bmj.298.6679.991 · Cited by 272
QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience
De Ponti, F., Poluzzi, E., & Montanaro, N. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050714 · Cited by 240
A self report measure of affective lability
Moore, S. R., Gresham, L. S., Bromberg, M. B., Kasarkis, E. J., & Smith, R. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.1.89 · Cited by 240
Treatment of Pathologic Laughing and Weeping with Amitriptyline
Schiffer, R. B., Herndon, R. M., & Rudick, R. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122303 · Cited by 233
Self-citationCitalopram for post-stroke pathological crying
Andersen, G., Vestergaard, K., & Riis, J. O. (1993) · The Lancet · doi:10.1016/0140-6736(93)92696-q · Cited by 232
Prevalence and Neurobehavioral Correlates of Pathological Laughing and Crying in Multiple Sclerosis
Feinstein, A., Feinstein, K., Gray, T., & O'Connor, P. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550210050012 · Cited by 189
Panitch, H. S., Thisted, R. A., Smith, R. A., Wynn, D. R., Wymer, J. P., Achiron, A., Vollmer, T. L., Mandler, R. N., Dietrich, D. W., Fletcher, M., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20828 · Cited by 174
Self-citationDextrorphan and dextromethorphan attenuate glutamate neurotoxicity
Choi, D. W. (1987) · Brain Research · doi:10.1016/0006-8993(87)90070-9 · Cited by 161
Pathologic Laughing and Crying Treated With Levodopa
Udaka, F., Yamao, S., Nagata, H., Nakamura, S., & Kameyama, M. (1984) · Archives of Neurology · doi:10.1001/archneur.1984.04050210093023 · Cited by 151
Pathologic laughter and crying in ALS: a search for their origin
Gallagher, J. P. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb03851.x · Cited by 132
Sertraline in stroke-associated lability of mood
Burns, A. S., Russell, E., Stratton‐Powell, H., Tyrrell, P. J., O'Neill, P. A., & Baldwin, R. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199908)14:8<681::aid-gps49>3.0.co;2-z · Cited by 120
Pathological Laughing and Crying Following Traumatic Brain Injury
Tateno, A., Jorge, R. E., & Robinson, R. G. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.4.426 · Cited by 117
Prevalence and clinical correlates of pathological affective display in Alzheimer's disease.
STARKSTEIN, S. E., Migliorelli, R., Teson, A., Petracca, G., Chemerinski, E., Manes, F. F., & Leiguarda, R. C. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.1.55 · Cited by 111
Paroxetine versus citalopram treatment of pathological crying after brain injury
Müller, U., Murai, T., Bauer-Wittmund, T., & von Cramon, D. Y. (1999) · Brain Injury · doi:10.1080/026990599121197 · Cited by 111
Pathological Laughing and Crying
Dark, F. L., McGrath, J. J., & Ron, M. A. (1996) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679609065020 · Cited by 106
Smith, R. A., Berg, J. E., Pope, L. E., Callahan, J. D., Wynn, D. R., & Thisted, R. A. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1106oa · Cited by 101
Self-citationFluoxetine improves emotional incontinence
Seliger, G. M., Hornstein, A., Flax, J. W., Herbert, J., & Schroeder, K. (1992) · Brain Injury · doi:10.3109/02699059209029668 · Cited by 97
Zhang, Y., Britto, M. R., Valderhaug, K. L., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.77 · Cited by 89
Musacchio, J. M., Klein, M., & Paturzo, J. J. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10081-3 · Cited by 82
Jackson, C. E., & Bryan, W. W. (1998) · Seminars in Neurology · doi:10.1055/s-2008-1040859 · Cited by 79
Cited by
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.71 · Cited by 1,414
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Self-citationMitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
Self-citationCummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Self-citation
Metadata
- Authors
- Pioro, E. P., Brooks, B. R., Cummings, J., Schiffer, R., Thisted, R. A., Wynn, D., Hepner, A., & Kaye, R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-09-13
- Volume
- 68
- Issue
- 5
- Pages
- 693-702
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1996649698
- Cited by
- 370
- References
- 32
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.